Yet, revamping technology and risk management framework might elevate expenses. Dupixent Profits Fuels Regeneron (REGN), Eylea Decline A Woe Per the Zacks analyst, stellar performance of Dupixent fuel, REGN even as lead drug Eylea faces disruption. The company's progress with the oncology portfolio & other candidates is also impressiv Norfolk Southern (NSC) Strong on Dividends Amid Volume Woes The Zacks analyst likes the company's efforts to reward its shareholders. However, below-par volumes due to weak freight-demand scenario remain a concern. YUM! Brands (YUM) Banks on Digital Efforts Amid High Costs Per the Zacks analyst, YUM! Brands focus on digital initiatives and refranchising efforts bode well. However, challenging macro environment, high labor costs and commodity inflation are concerns.